Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,533
archived clinical trials in
Kidney Cancer

Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Geisinger Medical Group - Scenery Park
mi
from
State College, PA
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Geisinger Medical Group - Scenery Park
mi
from
State College, PA
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Mary Babb Randolph Cancer Center at West Virginia University Hospitals
mi
from
Morgantown, WV
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Mary Babb Randolph Cancer Center at West Virginia University Hospitals
mi
from
Morgantown, WV
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Union Hospital of Cecil County
mi
from
Elkton, MD
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Union Hospital of Cecil County
mi
from
Elkton, MD
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Foote Memorial Hospital
mi
from
Jackson, MI
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Foote Memorial Hospital
mi
from
Jackson, MI
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses
Status: Enrolling
Updated:  12/20/2017
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses
Status: Enrolling
Updated: 12/20/2017
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses
Status: Enrolling
Updated:  12/20/2017
H. Lee Moffitt Cancer Center & Research Center
mi
from
Tampa, FL
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses
Status: Enrolling
Updated: 12/20/2017
H. Lee Moffitt Cancer Center & Research Center
mi
from
Tampa, FL
Click here to add this to my saved trials
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses
Status: Enrolling
Updated:  12/20/2017
Lahey Clinic
mi
from
Burlington, MA
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses
Status: Enrolling
Updated: 12/20/2017
Lahey Clinic
mi
from
Burlington, MA
Click here to add this to my saved trials
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses
Status: Enrolling
Updated:  12/20/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses
Status: Enrolling
Updated: 12/20/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses
Status: Enrolling
Updated:  12/20/2017
Duke Univ Med Ctr
mi
from
Durham, NC
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses
Status: Enrolling
Updated: 12/20/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses
Status: Enrolling
Updated:  12/20/2017
Ohio State University
mi
from
Columbus, OH
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses
Status: Enrolling
Updated: 12/20/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses
Status: Enrolling
Updated:  12/20/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses
Status: Enrolling
Updated: 12/20/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses
Status: Enrolling
Updated:  12/20/2017
MD Anderson
mi
from
Houston, TX
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses
Status: Enrolling
Updated: 12/20/2017
MD Anderson
mi
from
Houston, TX
Click here to add this to my saved trials
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
A Phase II Trial of Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  1/1/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
A Phase II Trial of Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 1/1/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
A Phase II Trial of Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  1/1/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
A Phase II Trial of Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 1/1/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
A Phase II Trial of Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  1/1/2018
Vanderbilt Univeristy Medical Center
mi
from
Nashville, TN
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
A Phase II Trial of Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 1/1/2018
Vanderbilt Univeristy Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
Phase II Study of Perifosine for Patients With Metastatic Carcinoma of the Kidney Who Have Progressed on a VEGF Receptor Inhibitor
Status: Enrolling
Updated:  2/2/2018
Clinical Research Facility
mi
from
Louisville, KY
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
Phase II Study of Perifosine for Patients With Metastatic Carcinoma of the Kidney Who Have Progressed on a VEGF Receptor Inhibitor
Status: Enrolling
Updated: 2/2/2018
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
Phase II Study of Perifosine for Patients With Metastatic Carcinoma of the Kidney Who Have Progressed on a VEGF Receptor Inhibitor
Status: Enrolling
Updated:  2/2/2018
Clinical Research Facility
mi
from
Morristown, NJ
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
Phase II Study of Perifosine for Patients With Metastatic Carcinoma of the Kidney Who Have Progressed on a VEGF Receptor Inhibitor
Status: Enrolling
Updated: 2/2/2018
Clinical Research Facility
mi
from
Morristown, NJ
Click here to add this to my saved trials
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
Phase II Study of Perifosine for Patients With Metastatic Carcinoma of the Kidney Who Have Progressed on a VEGF Receptor Inhibitor
Status: Enrolling
Updated:  2/2/2018
Clinical Research Facility
mi
from
Armonk, NY
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
Phase II Study of Perifosine for Patients With Metastatic Carcinoma of the Kidney Who Have Progressed on a VEGF Receptor Inhibitor
Status: Enrolling
Updated: 2/2/2018
Clinical Research Facility
mi
from
Armonk, NY
Click here to add this to my saved trials
Interleukin-2 in Metastatic Kidney Cancer
Phase II Trial of Moderate Dose Bolus Interleukin-2 in Metastatic Kidney Cancer
Status: Enrolling
Updated:  2/6/2018
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Interleukin-2 in Metastatic Kidney Cancer
Phase II Trial of Moderate Dose Bolus Interleukin-2 in Metastatic Kidney Cancer
Status: Enrolling
Updated: 2/6/2018
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor
Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor
Status: Enrolling
Updated:  2/13/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor
Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor
Status: Enrolling
Updated: 2/13/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated:  3/6/2018
Stanford Univ Med Ctr
mi
from
Stanford, CA
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated: 3/6/2018
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated:  3/6/2018
Lineberger Cancer Center
mi
from
Chapel Hill, NC
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated: 3/6/2018
Lineberger Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated:  3/6/2018
The Cleveland Clinic, Taussig Cancer Institute
mi
from
Cleveland, OH
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated: 3/6/2018
The Cleveland Clinic, Taussig Cancer Institute
mi
from
Cleveland, OH
Click here to add this to my saved trials
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated:  3/6/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated: 3/6/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated:  3/6/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated: 3/6/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Biomarkers That Predict Response to High-Dose Aldesleukin in Patients With Metastatic Kidney Cancer or Metastatic Melanoma
Pilot Study to Identify Biomarkers That May Predict Response to High Dose IL-2
Status: Enrolling
Updated:  3/29/2018
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Biomarkers That Predict Response to High-Dose Aldesleukin in Patients With Metastatic Kidney Cancer or Metastatic Melanoma
Pilot Study to Identify Biomarkers That May Predict Response to High Dose IL-2
Status: Enrolling
Updated: 3/29/2018
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
Status: Enrolling
Updated:  3/30/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
Status: Enrolling
Updated: 3/30/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Kidney Cancer
Injection of Renal Cell Carcinoma Patients With Human and Mouse Prostate Specific Membrane Antigen (PSMA) DNA: A Phase I Trial to Assess Safety and Immune Response
Status: Enrolling
Updated:  4/24/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Vaccine Therapy in Treating Patients With Kidney Cancer
Injection of Renal Cell Carcinoma Patients With Human and Mouse Prostate Specific Membrane Antigen (PSMA) DNA: A Phase I Trial to Assess Safety and Immune Response
Status: Enrolling
Updated: 4/24/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials